Amitabha Chakrabarti, Haidar Ali Sk, Souvik Ghosh
Abstract
Cancer is one of the leading causes of morbidity and mortality worldwide & cancer pain is experienced by patients with advanced, metastatic and terminal disease. Buprenorphine, a partial µ-receptor agonist and antagonist at the kopioid receptor, shows no clinically relevant accumulation of active metabolites, and pharmacokinetics remain unchanged in renal insufficiency. In elderly cancer patients, the use of opioids for control of cancer pain is a therapeutic challenge, as these group of patients often associated with renal and hepatic comorbidity that limited the use of strong opioids like morphine.
Methods: A retrospective observational study was conducted in elderly patients to estimate the efficacy of transdermal buprenorphine patch for controlling of cancer pain as well as to assess the safety of the patch. For pain control Numerical Rating Score (NRS) was used & for safety assessment Grade 3 or 4 toxicity were recorded. Hepatic & renal toxicity were measured at baseline, at 1st month & at 3rd month of treatment & lastly at 6th month of treatment.
Results: Majority of the patients showing good to excellent global satisfaction with Buprenorphine patch and 57% of patients suffered from constipation along with 38% nausea & vomiting. It was found that there was a significant reduction in pain intensity from baseline with a p value of <0.05. There was no significant hepatic or renal toxicity found in the study.
Conclusion: Transdermal buprenorphine patch is effective and safe in elderly cancer patients for pain control. Further studies should be performed in order to find safe and effective opioid methods necessary to give greater insight into the difficult balance between analgesia and toxicity.
Efficacy and Safety of Transdermal Buprenorphine Patch for Cancer Pain Relief in Elderly Patients A Retrospective Study from a Tertiary Care Centre of Eastern India
Reference:
1. Mallath MK, Taylor DG, Badwe RA, Rath GK, Shanta V, Pramesh CS, et al — The growing burden of cancer in India: Epidemiology and social context. Lancet Oncol 2014; 15: e205-12.
2. Van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ — Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage 2016; 51: 1070-90.e9.
3. Dean M — Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28: 497e504.
4. Mercadante S, Arcuri E — Opioids and renal function. J Pain 2004; 5: 2e19.
5. McQuay HJ, Moore RA, Bullingham RES — Buprenorphine kinetics. Adv Pain Res Ther 1986; 8: 271e278.
6. Filitz J, Griessinger N, Sittl R — Effects of intermittent hemodialysis on buprenorphine and nor- buprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006; 10: 743e748.
7. Budd K — Buprenorphine: a review. Newmarket: Hayward Medical Communications, 2002.
8. Johnson RE, Fudala PJ, Payne R — Buprenorphine: Considerations for pain management. J Pain Symptom Manage 2005; 29: 297-326.
9. Vallerand AH — The use of long-acting opioids in chronic pain management. Nurs Clin North Am 2003, 38: 435-45.
10. Efficacy and Safety of Transdermal Buprenorphine: A Randomized, Placebo-Controlled Trial in 289 Patients with Severe Cancer Pain Poulain, Philippe et al. Journal of Pain and Symptom Management, Volume 36, Issue 2, 117-25.
